PALO ALTO, Calif. (PRWEB)
May 13, 2020

The global blockchain development company HashCash Consultants has its aim set on streamlining the complex process of drug research and clinical trials by collaborating with pharmaceutical companies and other medical counterparts. In the light of the ongoing COVID-19 pandemic, the company recently shared its post-lockdown plans of forming a consortium of pharma and medical goods manufacturers, to address the pain areas within the healthcare industry through blockchain solutions.

Talking about their post-lockdown plans, Raj Chowdhury, CEO of HashCash Consultants commented, “A blockchain network for consolidating the drug research and clinical trial process will be part of our medical supply chain initiative. We are in talks with pharma companies who have expressed interest in augmenting their existing system with DLT to eliminate the roadblocks to drug and vaccine development that they are currently facing. The aim is to make the process more coordinated and less time-consuming so that it can cater better to a global health crisis or in matters of any kind of drug development in the future.”

The process of drug development followed by clinical trials and approval from regulatory bodies for mass production and distribution is both length and complex, not to mention heavily uncoordinated. It might still work, although painstakingly in a normal drug development scenario. However, in the case of a pandemic caused by a novel virus, where vaccine development becomes the only hope for eradicating the disease, the process needs to be well-coordinated and streamlined.

The creation of a new vaccine comprises of clinical research followed by human trials. At present medical infrastructure takes months to develop a vaccine or drug, and then more time is required to mass-produce and distribute. The delay is caused due to the lack of a unified system that would aid in the coordination of all the participants including researchers and pharma companies.

As the vaccine reaches clinical trials, healthcare facilities, human subjects, and regulatory bodies join in as well. There are several stages in the trials which culminate after getting approval from the FDA or any other regulatory organization.

The ultimate stage is mass production and distribution where the responsibility falls upon manufacturing units, distribution networks, and storage facilities. As it can be seen, by nature it is a lengthy process with several participants, which nevertheless can be streamlined through blockchain integration.

Blockchain for Clinical Research and Vaccine Trials:

What HashCash proposes is to build a uniform and collaborative platform with a consortium of pharma companies to consolidate the entire process. The use of a blockchain network will aid in easy coordination among the research participants and other medical counterparts.

While enabling accurate management of all the critical data on the vaccine compounds, DLT will also ensure absolute transparency of the vaccine development process. The use of smart contracts and identity management through blockchain will streamline the clinical trials, by safeguarding the privacy and security of patient data.

Since everything will get updated on a shared and immutable platform, the regulatory bodies will be able to track the development and trial stages in real-time, ensuring fast approval of the vaccine for mass production.

Once the vaccine or drug compound is approved and goes to production, a blockchain-based medical supply chain takes it from there, the outline of which has already been shared by HashCash.

The post-pandemic plans announced by the California based global blockchain firm attests to its focus on addressing the problem areas within the healthcare industry and the resolve to be a significant contributor in its reformation.

About HashCash Consultants:

HashCash is a global software company. HashCash Blockchain products enable enterprises to move assets and settle payments across borders in real-time for Remittances, Trade Finance, Payment Processing, and more. HashCash runs US-based digital asset exchange, PayBito & digital asset payment processor, BillBitcoins. HashCash offers exchange and payment processor software solutions, ICO Services, and customized use cases. HashCash propels advancement in technology through Blockchain1o1 programs and its investment arm, Satoshi Angels. HashCash offers solutions in AI, Big Data, and IoT through its platforms, products & services. HashCash solves the toughest challenges by executing innovative digital transformation strategies for clients around the world.

Share article on social media or email:

NEW YORK (PRWEB)
May 13, 2020

Unacast, an award-winning location data and analytics firm, announced that it is making its Social Distancing Scoreboard and other mobility data insights available as part of the ShopperTrak brand offerings from Sensormatic Solutions, the leading global retail solutions portfolio of Johnson Controls. Sensormatic Solutions will include insights powered by Unacast’s Real World Graph® data engine, to help retailers protect its employees, customers, and assets in brick-and-mortar store operations and warehouses amid the COVID-19 pandemic.

Sensormatic Solutions is adding Unacast’s opt-in, location-based data as a complement to ShopperTrak’s in-store Market Intelligence traffic benchmarking to provide insights to when and where retail will recover by understanding consumer mobility patterns and people’s comfort with public spaces. Unacast’s Social Distancing Scoreboard is an easy to reference dashboard which layers statistics related to new reported cases with changes in mobility and non-essential store visits, providing daily community grades (A to F) to help retailers evaluate reopening individual store locations across their enterprise.

Unacast’s Social Distancing Scoreboard, launched in mid-March, has been widely adopted by business leaders, public health experts, policy makers, academics, and community leaders as a way to communicate the importance of social distancing, and to provide insights into current public behavior and unearth trends for future scenarios related to the spread of COVID-19 across states and counties in the United States. In addition to the US, Unacast recently expanded its toolkit to track social distancing behavior in more than 100 countries.

For its Social Distancing Scoreboard, Unacast applied geospatial human mobility insights with its proprietary tools to create an interactive map showing mobility trends by county or by state as a way to raise awareness of and reinforce the importance of social distancing in relation to slowing the spread of COVID-19. The Scorecard’s A through F letter grade for all states and counties in relation to social distancing behavior uses three metrics that are then compared to the number of new COVID-19 cases reported in those areas to assign letter grades to help users draw conclusions between social distancing behavior and virus spread over time.

Unacast’s Social Distancing Scoreboard provides three key metrics:

• 
  Change in distance traveled prior to COVID-19 in comparison to present-day (areas that observe at least a 70% decrease in average distance traveled are assigned a grade of A, while those that exhibit less than a 25% decrease or increase are assigned an F.);
• Change in visitation to non-essential venues compared to a pre-COVID-19 period;
• Change in human encounters, or the probability that two devices that were in the same place at the same time compared to a pre-COVID-19 period.

“We are honored to be included in Sensormatic’s offering to retailers along with ShopperTrak,” said Thomas Walle, CEO and Co-founder at Unacast. “We have seen how powerful our tools have been in helping businesses mitigate the pandemic spread. As the business world looks ahead to forecasting recovery, we’ve designed our insight offerings to help retailers guide critical decision making and planning in the most timely and accurate way possible.”

“As retailers look to restore consumer confidence in this new reality, our goal is to provide ways to understand shopper density within a store for compliance with social distancing guidelines or ordinances, and to meet maximum limits,” said Nick Pompa, global general manager, ShopperTrak. “We believe Unacast’s proprietary technology and approach can help our clients as they navigate an unprecedented and challenging business climate.”

Unacast developed the Covid-19 Toolkit with public datasets, as well as aggregate mobility and anonymous device data from tens of millions of devices. Unacast’s proprietary technology then extrapolates the results to show trends by county and by state. As with all Unacast technology, the Toolkit follows GDPR and CCPA guidelines.

About Unacast

Unacast is an award-winning human mobility data company that harnesses anonymous device location data, map data, and strategic intelligence to tackle business challenges for the retail, real estate, tourism, transportation, and marketing industries. With its flagship product “The Real World Graph®”, it provides innovative solutions and insights to operational challenges for companies of any size or shape. Unacast was founded in 2014 with offices in New York and Oslo, Norway. In 2019, Unacast was awarded the #1 small company to work in NYC for by Built In NYC and received Street Fights’ Most Innovative Use of Geospatial Technology award.

About Sensormatic Solutions

Sensormatic Solutions is the leading global retail solutions portfolio of Johnson Controls enabling smart and connected shopper engagement. By combining critical insights into retail inventory, shopper traffic and loss prevention, Sensormatic Solutions powers operational excellence at scale and helps create unique shopping experiences. Our solutions deliver real-time visibility and predictive analytics for accurate decision-making across the enterprise, enabling retailers to confidently move into the future. With more than 1.5 million data collection devices in the retail marketplace, we capture 40 billion shopper visits and track and protect billions of items each year. Our retail portfolio features the premier Sensormatic, ShopperTrak and TrueVUE brands. Please visit http://www.sensormatic.com, or follow us on LinkedIn, Twitter, and our YouTube channel.

For more information and the full portfolio of current Sensormatic Solutions products and offerings in response to COVID-19, please visit Sensormatic.com. Additional solutions are expected to be launched in the coming weeks as well.

© 2020 Johnson Controls. All Rights Reserved. SENSORMATIC, SHOPPERTRAK, TRUEVUE and the product names listed above are trademarks and/or registered trademarks. Unauthorized use is strictly prohibited.

Media Contacts:

Bianca Ilion

Kite Hill on behalf of Unacast

bianca@kitehillpr.com

Gay A Gagliardi

Sensormatic Solutions by Johnson Controls

Work +1 561-912-6750

gay.gagliardi@jci.com

Ryan Nolan

Johnson Controls

Work +1 414-524-6170

ryan.p.nolan@jci.com

Anne Lines

Matter on behalf of Sensormatic Solutions

Work + 1 978-518-4512

JCIretail@matternow.com

Share article on social media or email:

Dr. Mario Almanza

TIJUANA, Mexico (PRWEB)
May 13, 2020

General Bariatric Surgeon Dr. Mario Almanza knows how effective procedures like gastric sleeve, gastric bypass and lap band surgery can be for enabling successful, long-term weight loss and the healthier, slimmer body patients deserve.

But Dr. Almanza also knows how important a healthy recovery process is to surgical success and how critical the right post-op behaviors are to achieving good health and sustained weight loss long after the patient has healed.

Below, Dr. Mario Almanza offers his take on what each weight loss patient should do during those important days and months after surgery – and how adhering to the right recovery plan can empower faster healing and make coping with post-op challenges just a little bit easier.

1. Speak with your bariatric care team before going home:

Dr. Mario Almanza has performed thousands of weight-loss surgeries. And after each procedure, Dr. Almanza and his team have taken great care to supply each patient with the information they need to enjoy the safest recovery possible.

Once your surgery is over, be sure to consult with your bariatric physician about everything you’ll need to optimize healing and avoid potential side effects. Ask any/all questions you have about recovery, what you’ll need to eat (post-op diet) and what resources are out there to make the process smoother.

2. Adhere to your medication plan:

As Dr. Almanza knows, the level of discomfort and pain patients experience post-op is highly personalized, depending largely on such factors as the type of bariatric procedure performed, the individual patient’s level of pain tolerance and their unique state of health.

But regardless of the situation, Dr. Mario Almanza recommends sticking to the pain management plan prescribed by the physician, and speaking out if pain and discomfort persist in spite of the medication. Doing so allows your bariatric team to monitor your progress and prescribe solutions when things don’t appear to be working.

3. Prevent complications by following instructions:

Bariatric surgery is generally pretty safe. Still, it’s crucial to adhere to any/all post-op instructions your surgical team provides to minimize complications that can hinder a successful recovery.

Dr. Mario Almanza recommends following each post-op instruction to the letter throughout your recovery, no matter how banal or unnecessary any steps may seem.

4. Optimize your at-home recovery environment:

Once you leave the hospital or post-op ward, it’s important to have a comfortable at-home environment to return to and begin your recovery process.

Dr. Almanza and his team recommend arranging such an environment beforehand and ensuring you have the post-op foods, entertainment options and comfy bed/couch areas ready once you’re given the green light to go home.

5. Stay in touch with your physician:

As Dr. Mario Almanza knows, sticking to follow-up appointments and updating your physician on your progress are critical to achieving a successful recovery. Be sure to consult your doctor should you experience any abnormal post-op swelling, illness or side effects, and always ask questions when needed.

About: Dr. Mario Almanza is a leading gastric sleeve surgeon in Tijuana. To date, Dr. Almanza has successfully performed more than 16,000 bariatric procedures.

Contact:

Dr. Mario Almanza

General Bariatric Surgeon; Laparoscopic Bariatric Surgeon

Phone: (855) 753-3833

Web: https://www.marioalmanza.com/

Share article on social media or email:

SOMERSET, N.J. (PRWEB)
May 13, 2020

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeted at COVID-19. Under the terms of the agreement, Catalent will develop a powder-in-capsule formulation of Ennaid’s ENU200 program, a patent-pending, repurposed oral antiviral drug.

ENU200 was selected by Ennaid as a candidate to treat COVID-19 following a bioinformatic search for in silico identification of prior-approved chemical compounds blocking the coronavirus proteins, spike-S glycoprotein and the key coronavirus enzyme, Mpro. Catalent’s development site at San Diego will manufacture roller-compacted formulations of ENU200 within capsules for further investigation.

“During this pandemic we have seen that numerous companies are looking to repurpose existing antiviral drugs to target COVID-19, and we are supporting our development partners in reacting quickly and effectively to manufacture material for clinical trials,” commented Jonathan Arnold, President, Oral and Specialty Delivery at Catalent. “Our experience with similar formulation and manufacturing processes and overcoming scale up challenges with roller compaction has meant that we are able to rapidly deliver Ennaid’s demand for drug product in a matter of weeks.”

Catalent’s San Diego facility is one of three global centers of excellence in early-phase development focusing on preclinical to clinical Phase 2b formulation, analytical, and manufacturing solutions for orally delivered small molecules, the other two being located in Somerset, New Jersey and Nottingham, U.K. The three strategically-located sites are closely connected to the company’s clinical supply services network, to optimize the transition from finished dose manufacture to clinical packaging and distribution.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

About Ennaid Therapeutics

Ennaid is a specialty pharmaceutical company using state-of-the-art artificial intelligence-based drug discovery platforms to develop broad-spectrum antiviral drugs that treat diseases in the Flaviviridae and Coronaviridae family of viruses, specifically SARS-CoV-2, the virus that causes COVID-19. The company has identified 112 additional compounds that may treat COVID-19 and other coronaviruses. Since inception, Ennaid has focused on the treatment of mosquito-borne diseases including Zika virus and dengue virus, which have caused pandemics. Their pipeline includes twelve additional indications. These programs were entering preclinical testing and have been placed on hold so that Ennaid can focus on developing a COVID-19 therapeutic. For more information visit, http://www.ennaidthera.com.

Share article on social media or email: